Belongs to

• Solid Tumor Oncology Division

Types of Work

["2019"]

[[["Meeting Abstracts",209],["Journal Articles",187],["Reviews",5],["Editorials",3],["Research Letters",3],["Book Sections",1]]]

[408]

Popular keywords

• adult
• aged
• article
• controlled study
• female
• gene mutation
• human
• major clinical study
• male
• priority journal

Recent Works

1. Avelumab plus talazoparib in patients with BRCA1/2- or ATM-altered advanced solid tumors: Results from JAVELIN BRCA/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial

   Journal Article

   Schram, A. M.; Colombo, N.; Arrowsmith, E.; Narayan, V.; Yonemori, K.; Scambia, G.; Zelnak, A.; Bauer, T. M.; Jin, N.; Ulahannan, S. V.; more...
   JAMA Oncology (2023)

   Fulltext@MSK | Save
2. Avelumab plus talazoparib in patients with advanced solid tumors: The JAVELIN PARP Medley nonrandomized controlled trial

   Journal Article

   Yap, T. A.; Bardia, A.; Dvorkin, M.; Galsky, M. D.; Beck, J. T.; Wise, D. R.; Karyakin, O.; Rubovszky, G.; Kislov, N.; Rohrberg, K.; more...
   JAMA Oncology (2023)

   Fulltext@MSK | Save
3. PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations

   Meeting Abstract

   Yap, T. A.; Im, S. A.; Schram, A. M.; Sharp, A.; Balmana, J.; Baird, R. D.; Brown, J. S.; Schwaederle, M.; Pilling, E. A.; Moorthy, G.; more...
   Cancer Research (2022)

   Fulltext@MSK | Save